TY - JOUR
T1 - Long-term Survival After Endoscopic Resection For Gastric Cancer
T2 - Real-world Evidence From a Multicenter Prospective Cohort
AU - J-WEB/EGC group
AU - Suzuki, Haruhisa
AU - Ono, Hiroyuki
AU - Hirasawa, Toshiaki
AU - Takeuchi, Yoji
AU - Ishido, Kenji
AU - Hoteya, Shu
AU - Yano, Tomonori
AU - Tanaka, Shinji
AU - Toya, Yosuke
AU - Nakagawa, Masahiro
AU - Toyonaga, Takashi
AU - Takemura, Kenichi
AU - Hirasawa, Kingo
AU - Matsuda, Mitsuru
AU - Yamamoto, Hironori
AU - Tsuji, Yosuke
AU - Hashimoto, Satoru
AU - Yuki, Maeda
AU - Oyama, Tsuneo
AU - Takenaka, Ryuta
AU - Yamamoto, Yoshinobu
AU - Naito, Yuji
AU - Yamamoto, Katsumi
AU - Kobayashi, Nozomu
AU - Kawahara, Yoshiro
AU - Hirano, Masaaki
AU - Koizumi, Shigeto
AU - Hori, Shinichiro
AU - Tajika, Masahiro
AU - Hikichi, Takuto
AU - Yao, Kenshi
AU - Yokoi, Chizu
AU - Ohnita, Ken
AU - Hisanaga, Yasuhiro
AU - Sumiyoshi, Tetsuya
AU - Kitamura, Shinji
AU - Tanaka, Hisao
AU - Shimoda, Ryo
AU - Shimazu, Taichi
AU - Takizawa, Kohei
AU - Tanabe, Satoshi
AU - Kondo, Hitoshi
AU - Iishi, Hiroyasu
AU - Ninomiya, Motoki
AU - Oda, Ichiro
AU - Mashimo, Yumi
AU - Ishigooka, Masahiro
AU - Fukase, Kazutoshi
AU - Mizuguchi, Yasuhiko
N1 - Funding Information:
Funding The current study was supported by a grant for Clinical Cancer Research from the Japanese Ministry of Health , Labour, and Welfare (H21-022), a grant from Daiwa Securities Health Foundation, Japan (H24-16), and a grant for the National Cancer Center Research and Development from the Japanese Ministry of Health , Labour, and Welfare (25-A-12, 28-K-1, 29-A-13).
Publisher Copyright:
© 2023 AGA Institute
PY - 2023/2
Y1 - 2023/2
N2 - Background & Aims: We aimed to clarify the long-term outcomes of endoscopic resection (ER) for early gastric cancers (EGCs) based on pathological curability in a multicenter prospective cohort study. Methods: We analyzed the long-term outcomes of 9054 patients with 10,021 EGCs undergoing ER between July 2010 and June 2012. Primary endpoint was the 5-year overall survival (OS). The hazard ratio for all-cause mortality was calculated using the Cox proportional hazards model. We also compared the 5-year OS with the expected one calculated for the surgically resected patients with EGC. If the lower limit of the 95% confidence interval (CI) of the 5-year OS exceeded the expected 5-year OS minus a margin of 5% (threshold 5-year OS), ER was considered to be effective. Pathological curability was categorized into en bloc resection, negative margins, and negative lymphovascular invasion: differentiated-type, pT1a, ulcer negative, ≤2 cm (Category A1); differentiated-type, pT1a, ulcer negative, >2 cm or ulcer positive, ≤3 cm (Category A2); undifferentiated-type, pT1a, ulcer negative, ≤2 cm (Category A3); differentiated-type, pT1b (SM1), ≤3 cm (Category B); or noncurative resections (Category C). Results: Overall, the 5-year OS was 89.0% (95% CI, 88.3%–89.6%). In a multivariate analysis, no significant differences were observed when the hazard ratio of Categories A2, A3, and B were compared with that of A1. In all the pathological curability categories, the lower limit of the 95% CI for the 5-year OS exceeded the threshold 5-year OS. Conclusion: ER can be recommended as a standard treatment for patients with EGCs fulfilling Category A2, A3, and B, as well as A1 (UMIN Clinical Trial Registry, UMIN000005871).
AB - Background & Aims: We aimed to clarify the long-term outcomes of endoscopic resection (ER) for early gastric cancers (EGCs) based on pathological curability in a multicenter prospective cohort study. Methods: We analyzed the long-term outcomes of 9054 patients with 10,021 EGCs undergoing ER between July 2010 and June 2012. Primary endpoint was the 5-year overall survival (OS). The hazard ratio for all-cause mortality was calculated using the Cox proportional hazards model. We also compared the 5-year OS with the expected one calculated for the surgically resected patients with EGC. If the lower limit of the 95% confidence interval (CI) of the 5-year OS exceeded the expected 5-year OS minus a margin of 5% (threshold 5-year OS), ER was considered to be effective. Pathological curability was categorized into en bloc resection, negative margins, and negative lymphovascular invasion: differentiated-type, pT1a, ulcer negative, ≤2 cm (Category A1); differentiated-type, pT1a, ulcer negative, >2 cm or ulcer positive, ≤3 cm (Category A2); undifferentiated-type, pT1a, ulcer negative, ≤2 cm (Category A3); differentiated-type, pT1b (SM1), ≤3 cm (Category B); or noncurative resections (Category C). Results: Overall, the 5-year OS was 89.0% (95% CI, 88.3%–89.6%). In a multivariate analysis, no significant differences were observed when the hazard ratio of Categories A2, A3, and B were compared with that of A1. In all the pathological curability categories, the lower limit of the 95% CI for the 5-year OS exceeded the threshold 5-year OS. Conclusion: ER can be recommended as a standard treatment for patients with EGCs fulfilling Category A2, A3, and B, as well as A1 (UMIN Clinical Trial Registry, UMIN000005871).
KW - Early Gastric Cancer
KW - Endoscopic Resection
KW - Endoscopic Submucosal Dissection
KW - Long-term Survival
KW - Multicenter Prospective Cohort Study
UR - http://www.scopus.com/inward/record.url?scp=85140318650&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140318650&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2022.07.029
DO - 10.1016/j.cgh.2022.07.029
M3 - Article
C2 - 35948182
AN - SCOPUS:85140318650
SN - 1542-3565
VL - 21
SP - 307-318.e2
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 2
ER -